Showing results (231-240 of 242) with videos related to
Sort By:
Pageof 25
British Journal of Cancer|September 1, 1993
A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancerE G de Vries, J A Gietema, P Workman, et al.British Journal of Cancer|October 27, 2005
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026B P Nutley, N F Smith, A Hayes, et al.British Journal of Cancer|October 14, 2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end pointsA O'Donnell, A Padhani, C Hayes, et al.British Journal of Cancer|August 15, 2013
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRIM Beloueche-Babari, Y Jamin, V Arunan, et al.British Journal of Cancer|October 2, 2003
In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotopeD R Collingridge, M Glaser, S Osman, et al.British Journal of Cancer|December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysC Benson, J White, J De Bono, et al.Analytical Biochemistry|February 8, 2006
A fluorescence polarization assay for inhibitors of Hsp90R Howes, X Barril, B W Dymock, et al.British Journal of Cancer|November 26, 2009
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopyC P Lee, G S Payne, A Oregioni, et al.Leukemia|February 23, 2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsA S Moore, A Faisal, D Gonzalez de Castro, et al.British Journal of Cancer|May 27, 2010
Guidelines for the welfare and use of animals in cancer researchP Workman, E O Aboagye, F Balkwill, et al.Pageof 25